All In Biotech

Drug Trial Radar · NCT04072952

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

A Phase 1/2, Open Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer, Who Have Received Prior Hormonal Therapy and Chemotherapy in the Locally Advanced/Metastatic Setting

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

219

Actual

Start

Sep 22, 2019

Primary completion

Sep 13, 2024

Study completion Mar 5, 2026

Sponsor

Sponsor type
Industry
Collaborators
Pfizer
First posted
Aug 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 1/2 dose escalation and cohort expansion study and assessed the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or mBC, who had received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.

Conditions

  • Breast Cancer

Interventions

  • VepdegestrantDrug

    Vepdegestrant administered QD for 28-day cycles

  • VepdegestrantDrug

    Vepdegestrant administered QD or BID for 28-day cycles.

  • PalbociclibDrug

    Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of TreatmentTime frame: Baseline (Day 1) up to C1D28
  2. Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)
  3. Part B: Clinical Benefit Rate (CBR)Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
  4. Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of TreatmentTime frame: Baseline (Day 1) up to C1D28
  5. Part C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)
  6. Part C: Maximum Tolerated Dose (MTD)Time frame: Baseline (Day 1) up to C1D28

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Palo Alto, California

  • Clinical Trial Site

    San Francisco, California

  • Clinical Trial Site

    Santa Monica, California

  • Clinical Trial Site

    Norwalk, Connecticut

  • Clinical Trial Site

    Fort Myers, Florida

  • Clinical Trial Site

    Tampa, Florida

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Ann Arbor, Michigan

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    East Brunswick, New Jersey

  • Clinical Trial Site

    The Bronx, New York

  • Clinical Trial Site

    Charlotte, North Carolina

  • Clinical Trial Site

    Nashville, Tennessee

  • Clinical Trial Site

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.